NO950725L - Pressure transdermal drug delivery device - Google Patents

Pressure transdermal drug delivery device

Info

Publication number
NO950725L
NO950725L NO950725A NO950725A NO950725L NO 950725 L NO950725 L NO 950725L NO 950725 A NO950725 A NO 950725A NO 950725 A NO950725 A NO 950725A NO 950725 L NO950725 L NO 950725L
Authority
NO
Norway
Prior art keywords
drug
hours
patient
layer
delivery
Prior art date
Application number
NO950725A
Other languages
Norwegian (no)
Other versions
NO950725D0 (en
Inventor
Jesus Miranda
Gary W Cleary
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Publication of NO950725D0 publication Critical patent/NO950725D0/en
Publication of NO950725L publication Critical patent/NO950725L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Transdermal medlkament-avleverlngsinnretning (10) som kan bil båret av en menneskelig pasient i 24 timer, mens den kontinuerlig avleverer et medikament til pasienten tilnærmet 16 timer, blir fremstilt ved en spesiell fremstilllngsmetode. Innretningen (10) er særlig nyttig med hensyn på avlevering av medikamenter, som dersom de blir avlevert i 24 timer, resulterer l problemer slik som medlkamenttoleranse (for eksempel nitroglycerin) eller søvnforstyrrelser (for eksempel nikotin). Medikamentet blir ladd i innretningen (10) l en konsentrasjon slik at medikamentet blir uttømt fra innretningen etter tilnærmet 16 timer l en slik grad at avleverlngshastlgheten av medikament til pasienten synker l en slik grad at den farmakologiske effekten av medikamentet på pasienten hovedsakelig blir ikke- ekslsterende. Innretningen (10) er l form av en laminert komposltt som er tilpasset til å bil festet til et bestemt område av ubrutt hud eller mukosavev. De individuelle lagene av innretningen Innbefatter et øvre bak eller, "ytre hud" lag (11), et ankeradhesivt lag (12), et kildelag (13) i hvilket medikament og/eller bærere til å begynne med er avsatt, et kontaktadhesiv (14) som er tilpasset til å festes til hud eller mukosa, og et frlgjørlngslag (15).Transdermal drug delivery device (10) capable of being carried by a human patient for 24 hours while continuously delivering a drug to the patient for approximately 16 hours is prepared by a special method of preparation. The device (10) is particularly useful in the delivery of medications which, if delivered for 24 hours, result in problems such as drug tolerance (eg nitroglycerin) or sleep disorders (eg nicotine). The drug is charged into the device (10) at a concentration such that the drug is discharged from the device after approximately 16 hours to such a degree that the delivery rate of drug to the patient decreases to such a degree that the pharmacological effect of the drug on the patient is mainly non-exterminating. . The device (10) is in the form of a laminated composite adapted to car attached to a specific area of unbroken skin or mucosal tissue. The individual layers of the device include an upper back or, "outer skin" layer (11), an anchor adhesive layer (12), a source layer (13) into which drug and / or carriers are initially deposited, a contact adhesive (14). ) which is adapted to attach to skin or mucosa, and a finishing layer (15).

NO950725A 1992-08-25 1995-02-24 Pressure transdermal drug delivery device NO950725L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93504492A 1992-08-25 1992-08-25
PCT/US1992/010672 WO1994004109A1 (en) 1992-08-25 1992-12-10 Printed transdermal drug delivery device

Publications (2)

Publication Number Publication Date
NO950725D0 NO950725D0 (en) 1995-02-24
NO950725L true NO950725L (en) 1995-04-10

Family

ID=25466511

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950725A NO950725L (en) 1992-08-25 1995-02-24 Pressure transdermal drug delivery device

Country Status (8)

Country Link
EP (1) EP0656771A4 (en)
JP (1) JPH08502727A (en)
KR (1) KR950702811A (en)
AU (1) AU3247193A (en)
CA (1) CA2142871A1 (en)
FI (1) FI950766A (en)
NO (1) NO950725L (en)
WO (1) WO1994004109A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649534B4 (en) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Packing made of composite packaging for packaging active ingredient-containing patches
DE19814084B4 (en) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
HU225734B1 (en) * 1999-07-28 2007-07-30 Zoltan Dardai Multilayer plaster for introducing peptidaceous pharmacons in living organisms and process for producing thereof
DE10110391A1 (en) 2001-03-03 2002-09-26 Lohmann Therapie Syst Lts Highly flexible nicotine transdermal therapeutic system with nicotine as active ingredient
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (en) 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
DE10261696A1 (en) 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
CA2544291C (en) 2003-10-27 2013-01-08 University Of Basel Transdermal drug delivery method and system
JP4745747B2 (en) 2004-08-12 2011-08-10 日東電工株式会社 Fentanyl-containing patch preparation
JP4824963B2 (en) 2004-08-12 2011-11-30 日東電工株式会社 Patch and patch preparation
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
IL177071A0 (en) * 2005-08-01 2006-12-10 Nitto Denko Corp Method of preparing a nicotine transdermal preparation
EP1774964B1 (en) 2005-10-13 2014-08-06 Nitto Denko Corporation Nicotine transdermal preparation and production method thereof
JP5535497B2 (en) * 2008-03-06 2014-07-02 リンテック株式会社 Transdermal patch
JP5460971B2 (en) * 2008-03-28 2014-04-02 リンテック株式会社 Transdermal patch
HUE027916T2 (en) * 2010-12-14 2016-11-28 Acino Ag Transdermal therapeutic system for application of an agent
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst Compositions and methods for treatment of symptoms in parkinson's disease patients
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
JP2018511127A (en) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Craving input and support system
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5016652A (en) * 1985-04-25 1991-05-21 The Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine

Also Published As

Publication number Publication date
KR950702811A (en) 1995-08-23
EP0656771A4 (en) 1996-07-31
FI950766A0 (en) 1995-02-20
JPH08502727A (en) 1996-03-26
EP0656771A1 (en) 1995-06-14
CA2142871A1 (en) 1994-03-03
WO1994004109A1 (en) 1994-03-03
AU3247193A (en) 1994-03-15
FI950766A (en) 1995-03-22
NO950725D0 (en) 1995-02-24

Similar Documents

Publication Publication Date Title
NO950725L (en) Pressure transdermal drug delivery device
US5635204A (en) Method for transdermal induction of anesthesia, analgesia or sedation
US11471424B2 (en) Biosynchronous transdermal drug delivery
EP0246385B1 (en) Transcutaneous application of nicotine
US5603947A (en) Method and device for providing nicotine replacement therapy transdermally/transbuccally
Madhav et al. Orotransmucosal drug delivery systems: a review
US4704119A (en) Method comprising transdermal and buccal treatment of angina
Svedmyr Fenoterol: A Beta2‐adrenergic Agonist for Use in Asthma; Pharmacology, Pharmacokinetics, Clinical Efficacy and Adverse Effects
MX9603667A (en) Drug-containing adhesive composite transdermal delivery device.
US5643905A (en) Pharmaceutical formulation for the treatment of nicotine dependence
CA2064687A1 (en) Method and device for administering dexmedetomidine transdermaly
JPH03504977A (en) Laminated composite for transdermal administration of fentanyl
EP1450773B1 (en) Transdermal therapeutic system provided with improved long-term carrying comfort
US6582737B2 (en) Pharmaceutical composition containing two active ingredients for smoking cessation
JPH09506331A (en) Therapeutic system for psoriasis treatment
Garry et al. Diurnal administration of human growth hormone-releasing factor does not modify sleep and sleep-related growth hormone secretion in normal young men
Stanley et al. Novel delivery systems: oral transmucosal and intranasal transmucosal
EA002197B1 (en) Transmucosal formulations of levosimendan
WO2003079976A3 (en) A substance with sedative effect
KR20010102239A (en) Pharmaceutical composition containing deoxypeganine for the treatment of drug dependence
JP2002514523A (en) Laminated products applied to the receiver
US20070265238A1 (en) Method for accelerating reentrainment of a circadian rhythm
Streisand et al. Newer drug delivery systems
Cuber et al. Role of cyclic nucleotides and calcium in the nutrient‐induced release of cholecystokinin‐like immunoreactivity in rats.
SU1648461A1 (en) Method for treatment of patients affected by panic attacks